Discover 3,592 paid clinical trials in Santa Ana, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,592
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
Location: Irvine CA, Duarte CA, Houston TX, Zion IL, Tucker GA,
Sponsor: Generate Biomedicines
Sex: All
Age: 18+
Code: NCT07484022
Phase 1, Recruiting
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
for
Clear Cell Renal Cell Carcinoma,
Location: Irvine CA, Duarte CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT07037004
Phase 2, Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
for
Chickenpox
Location: Huntington Park CA, Sherman Oaks CA, Tucson AZ,
Sponsor: GlaxoSmithKline
Sex: All
Age: 1
Code: NCT06855160
Phase 3, Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
for
Myeloproliferative Neoplasms
Location: Irvine CA, Nashville TN, Atlanta GA, Columbus OH,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT07441694
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
for
Alopecia Areata
Location: Los Angeles CA, Palm Springs CA, San Diego CA,
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Irvine CA, Beverly Hills CA, Goodyear AZ, Denver CO,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07589634
Phase 2, Recruiting
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning